Table 3.

Top 10 priority translational dermatology research questions on skin cancer (listed in alphabetical order).

Can the oncogenome of cutaneous SCC be used to predict response to novel targeted therapies?

Can we identify biomarkers of melanoma recurrence / tumour load to assist in the early detection of metastases and selecting patients for interventions such as vemurafenib and ipilimumab?

Can we identify novel systemic treatments for SCC?

Can we identify stratified therapies for melanoma?

Does the treatment of precancerous skin lesions i.e. actinic keratoses lead to a reduction in the development of squamous cell carcinoma?

What are the critical determinants of the tumour microenvironment that drive aggressive cutaneous SCC?

What are the genetic/molecular drivers for cutaneous SCC?

What are the predictive biomarkers of melanoma relapse?

What are the specific biomarkers associated with progress of dysplastic nevi to primary melanoma to metastatic melanoma in the same individual?

What factors drive the survival of melanoma cells that are apparently dormant and that lead to metastases, in some cases, decades after excision of the primary lesion?